[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100470145":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":24,"locations":30,"responsibleParty":47,"collaborators":50,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":10,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":10,"maxAge":10,"enrollmentInfo":61,"targetDuration":10,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":10,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"University of Texas Southwestern Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Survey \u002F Interview Group",null,"All patients (or parent \u002F caregiver, if relevant) who provide informed consent will be asked to complete baseline assessments utilizing validated questionnaires administered through the phone or video call. The clinical research coordinator will input responses into REDCap. Alternatively, patients may request assessments be sent through secure email.\n\nBaseline assessment consisting of sociodemographic items and study eligibility questions (call #1)\n\nIn addition, each patient will complete the Comprehensive Score for financial Toxicity Patient Reported Outcome Measure (COST PROM) and Short Assessment of Health Literacy (SAHL) survey measures.",[13],"Behavioral: Survey \u002F Interview Group",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":10},"BEHAVIORAL","Patients with any cancer type who are informed that they may be eligible for participation in any phase therapeutic cancer clinical trial by their treating physician (typically a clinical oncologist) will be provided information about the Financial Reimbursement Program. Patients who enroll to therapeutic cancer clinical trial will be eligible for the reimbursement program and offered an opportunity to participate in this study.",[9],[20],{"name":21,"affiliation":22,"role":23},"David E Gerber, MD","Professor","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Rebecca Renn","CONTACT","214-648-7097","Rebecca.Renn@utsouthwestern.edu",[31],{"facility":5,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"RECRUITING","Dallas","Texas","75390","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-96.80667,32.78306,{"lat":42,"lon":41},[45,46],{"name":21,"role":27,"phone":10,"phoneExt":10,"email":10},{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},{"type":23,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"David E Gerber","Professor, Internal Medicine",[51],{"name":52,"class":6},"Cancer Prevention Research Institute of Texas","100470145","cancer-clinical-trials-financial-reimbursement-program-100470145",false,"NCT05402033","Cancer Clinical Trials Financial Reimbursement Program","Enhancement of Access to and Diversity in Cancer Clinical Trials Through a Financial Reimbursement and Outreach Program","Inclusion Criteria:\n\n* Be enrolled in a therapeutic cancer clinical trial\n* Speak English or Spanish\n\nExclusion Criteria:\n\n* Not enrolled in a clinical trial\n* Does not speak English or Spanish","ALL",{"count":62,"type":63},1200,"ESTIMATED","OBSERVATIONAL","To implement a Financial Reimbursement and Outreach Program at clinical sites within the Harold C. Simmons Comprehensive Cancer Center; and evaluate the impact of the program on clinical trial enrollment and demographics, as well as facilitators of and barriers to program participation.",[67],"Cancer Clinical Trials","2026-07-16",{"date":70,"type":71},"2026-07-20","ACTUAL",{"date":73,"type":71},"2022-07-12",{"date":75,"type":63},"2030-06-01",{"name":5,"class":6},1]